BRPI0817397A2 - Compostos indol contendo grupos arila ou heteroarila com atividade biológica do receptor de esfingosina-1-fosfato (sip) - Google Patents

Compostos indol contendo grupos arila ou heteroarila com atividade biológica do receptor de esfingosina-1-fosfato (sip)

Info

Publication number
BRPI0817397A2
BRPI0817397A2 BRPI0817397A BRPI0817397A2 BR PI0817397 A2 BRPI0817397 A2 BR PI0817397A2 BR PI0817397 A BRPI0817397 A BR PI0817397A BR PI0817397 A2 BRPI0817397 A2 BR PI0817397A2
Authority
BR
Brazil
Prior art keywords
sphingosine
sip
biological activity
compounds containing
heteroaryl groups
Prior art date
Application number
Other languages
English (en)
Portuguese (pt)
Inventor
Richard L Beard
Haiqing Yuan
John E Donello
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of BRPI0817397A2 publication Critical patent/BRPI0817397A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/30Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Indole Compounds (AREA)
BRPI0817397 2007-09-24 2008-09-18 Compostos indol contendo grupos arila ou heteroarila com atividade biológica do receptor de esfingosina-1-fosfato (sip) BRPI0817397A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97451107P 2007-09-24 2007-09-24
PCT/US2008/076792 WO2009042485A1 (en) 2007-09-24 2008-09-18 Indole compounds bearing aryl or heteroaryl groups having sphingosine-1-phosphate (s1p) receptor biological activity

Publications (1)

Publication Number Publication Date
BRPI0817397A2 true BRPI0817397A2 (pt) 2015-04-07

Family

ID=40042883

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0817397 BRPI0817397A2 (pt) 2007-09-24 2008-09-18 Compostos indol contendo grupos arila ou heteroarila com atividade biológica do receptor de esfingosina-1-fosfato (sip)

Country Status (10)

Country Link
US (1) US7888336B2 (https=)
EP (1) EP2203424A1 (https=)
JP (1) JP2010540543A (https=)
KR (1) KR20100067677A (https=)
CN (1) CN101918360A (https=)
AU (1) AU2008304657B2 (https=)
BR (1) BRPI0817397A2 (https=)
CA (1) CA2700539A1 (https=)
RU (1) RU2010112275A (https=)
WO (1) WO2009042485A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006088246A1 (ja) * 2005-02-18 2006-08-24 Takeda Pharmaceutical Company Limited Gpr34受容体機能調節剤
US8524917B2 (en) * 2007-01-11 2013-09-03 Allergan, Inc. 6-substituted indole-3-carboxylic acid amide compounds having sphingosine-1-phosphate (S1P) receptor antagonist biological activity
JP2014518554A (ja) * 2011-04-18 2014-07-31 アラーガン インコーポレイテッド スフィンゴシン−1リン酸受容体調節剤としての置換二環式メチルアミン誘導体
GB201603745D0 (en) * 2016-03-04 2016-04-20 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of fibrosis

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4363912A (en) * 1980-12-15 1982-12-14 Pfizer Inc. Indole thromboxane synthetase inhibitors
EP0146810A3 (de) * 1983-12-05 1987-05-13 Solco Basel AG Verfahren zur Herstellung von Sphingosinderivaten
US5110987A (en) * 1988-06-17 1992-05-05 Emory University Method of preparing sphingosine derivatives
ZA902794B (en) * 1989-04-18 1991-04-24 Duphar Int Res New 3-n substituted carbamoyl-indole derivatives
US5294722A (en) * 1992-04-16 1994-03-15 E. R. Squibb & Sons, Inc. Process for the preparation of imidazoles useful in angiotensin II antagonism
US5403851A (en) * 1994-04-05 1995-04-04 Interneuron Pharmaceuticals, Inc. Substituted tryptamines, phenalkylamines and related compounds
US5639780A (en) * 1995-05-22 1997-06-17 Merck Frosst Canada, Inc. N-benzyl indol-3-yl butanoic acid derivatives as cyclooxygenase inhibitors
US5811425A (en) * 1997-03-04 1998-09-22 Abbott Laboratories Heterocyclic compounds as COX-2 inhibitors
ATE314342T1 (de) * 1997-03-12 2006-01-15 Takara Bio Inc Spingosinanaloga
ATE332888T1 (de) * 1997-09-11 2006-08-15 Takara Bio Inc Sphingosinderivate und medizinische zubereitung
US6358992B1 (en) * 1998-11-25 2002-03-19 Cell Pathways, Inc. Method of inhibiting neoplastic cells with indole derivatives
FR2814073B1 (fr) * 2000-09-21 2005-06-24 Yang Ji Chemical Company Ltd Composition pharmaceutique antifongique et/ou antiparasitaire et nouveaux derives de l'indole a titre de principes actifs d'une telle composition
US7074817B2 (en) * 2001-06-20 2006-07-11 Wyeth Substituted indole acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
JP4430941B2 (ja) 2002-01-18 2010-03-10 メルク エンド カムパニー インコーポレーテッド Edg受容体作動薬
CA2473740A1 (en) 2002-01-18 2003-07-31 David Solow-Cordero Methods of treating conditions associated with an edg receptor
US7323479B2 (en) 2002-05-17 2008-01-29 Celgene Corporation Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
PL378134A1 (pl) 2003-02-11 2006-03-06 Irm Llc Nowe pochodne bicykliczne i kompozycje farmaceutyczne zawierające pochodne bicykliczne
CN1777575B (zh) 2003-04-30 2010-05-12 诺瓦提斯公司 作为1-磷酸-鞘氨醇受体调节剂的氨基-丙醇衍生物
MY150088A (en) 2003-05-19 2013-11-29 Irm Llc Immunosuppressant compounds and compositions
US7582773B2 (en) * 2003-09-25 2009-09-01 Wyeth Substituted phenyl indoles
AU2007214434B2 (en) * 2006-02-15 2012-06-14 Allergan, Inc. Indole-3-carboxylic acid amide, ester, thioamide and thiol ester compounds bearing aryl or heteroaryl groups having sphingosine-1-phosphate (S1P) receptor antagonist biological activity
US8097644B2 (en) 2006-03-28 2012-01-17 Allergan, Inc. Indole compounds having sphingosine-1-phosphate (S1P) receptor antagonist

Also Published As

Publication number Publication date
KR20100067677A (ko) 2010-06-21
CA2700539A1 (en) 2009-04-02
RU2010112275A (ru) 2011-11-10
EP2203424A1 (en) 2010-07-07
US20100240614A1 (en) 2010-09-23
AU2008304657B2 (en) 2013-09-05
JP2010540543A (ja) 2010-12-24
AU2008304657A1 (en) 2009-04-02
WO2009042485A1 (en) 2009-04-02
US7888336B2 (en) 2011-02-15
CN101918360A (zh) 2010-12-15

Similar Documents

Publication Publication Date Title
BRPI0715324A2 (pt) Composto de indol
BRPI0909375A2 (pt) Moduladores de receptores de quimiocinas
EP2079466A4 (en) SUBSTITUTED INDOLE COMPOUNDS
ATE509927T1 (de) Indolderivate als s1p1-rezeptor-agonisten
BRPI0810365A2 (pt) Inibidores de mlc-1 de indol 7-substituído
BRPI0810613A2 (pt) derivados de tetra-hidrocarbazol como ligantes de receptores acoplados à proteína g
EP2150677A4 (en) STORAGE SYSTEM FOR DRILLING SYSTEM
BRPI0914942A2 (pt) Compostos de oxindol
BRPI0813678A8 (pt) polímeros funcionalizados com halossilanos contendo um grupo amino
BRPI0811503A2 (pt) Diagnótico de melanoma por análise de ácido nucleico
EP2478433A4 (en) ASSIGNMENT OF DATA SET ELEMENTS
BRPI0813653A2 (pt) Compostos de imidazotiazol moduladores de sirtuína
BRPI0818150A2 (pt) Diaminas unidas ou fusionadas substituídas com arila como moduladoras de leucotrieno a4 hidrolase
BRPI0920648A2 (pt) Combinações pesticidas contendo sulfoxaflor
DK2035396T3 (da) Triazolforbindelser der modulerer hsp90-aktivitet
BRPI0814028A2 (pt) sistema de calibração de biossensor
DE602005015962D1 (de) Indolylderivate als liver-x-rezeptormodulatoren
BRPI0809221A2 (pt) indol carboxamidas como inibidores de ikk2
DE602008002205D1 (de) Neuartige verbindungen
BR112013014854A8 (pt) compostos de n-(1h-indazol-4-il)imidazo [1,2-a] piridina-3-carboxamida substituídos como inibidores de tirosina quinase de receptor tipo iii
EP2232257A4 (en) Stabilization of test reagents on a solid surface
BRPI0818811A2 (pt) Temporizadores de descarte de unidade de dados de serviço
DE602008005140D1 (de) Organische verbindungen
BRPI0910585A2 (pt) indóis como moduladores de receptor de aceticolina nicotínica do subtipo alfa-7
BRPI0818338A2 (pt) Composto de pirimidil indolina

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 4A, 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.